Web21 mrt. 2024 · A novel fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PHESGO®, PH FDC SC) can be administered in approximately 5-8 min. PH FDC SC was non-inferior to IV pertuzumab plus trastuzumab in terms of pertuzumab and trastuzumab serum levels in the phase III FeDeriCa study, which … Web5 jul. 2024 · The drug, Phesgo, can be used for all stages of HER2-positive breast cancer. Experts say it can be administered at home by a healthcare professional more quickly …
NDC 50242-260 Phesgo Label Information
WebPhesgo will be administered subcutaneously (SC) at a fixed non-weight-based dose. In the induction therapy phase, a loading dose (1200 milligram (mg) pertuzumab, 600 mg trastuzumab, and 30,000 units of recombinant human PH20 hyaluronidase [rHuPH20]) will be administered in the first cycle (1 cycle is 21 days). Web23 jun. 2024 · Phesgo Injection, Subcutaneous Solution Pertuzumab is a humanized monoclonal antibody designed to bind to the HER2 receptor and inhibit the ability of HER2 to interact with other HER family members (HER1, HER2, HER3, and … cyt beach wagon
Phesgo FDA Approval History - Drugs.com
Web3 mei 2024 · Phesgo. Hi I've been on trastuzumub and pertuzumab since March, my last 3 times I've had the phesgo injection in alternate thighs each time, injection only takes 5 … Web25 mrt. 2024 · For men: participants who agree to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agree to refrain from donating sperm, during the treatment period and for 7 months after the final dose of Phesgo to avoid exposing the embryo Maintenance Phase Inclusion Criteria Complete a minimum of four … Web27 jul. 2024 · Anaphylaxis is a severe allergic reaction that can cause hives, low blood pressure, dizziness, chills, and trouble breathing. The healthcare provider who gives you the Phesgo injection will closely monitor you for 30 minutes after your first dose. For later doses, you will be monitored for 15 minutes. bind required c#